A Phase 1 Single and Multiple Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Healthy Participants (Part A) and the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SR604 in Participants with Hemophilia a or Hemophilia B (Part B)
Latest Information Update: 17 Mar 2025
At a glance
- Drugs SR 604 (Primary)
- Indications Haemophilia A; Haemophilia B
- Focus Adverse reactions; First in man
- Sponsors Equilibra Bioscience
- 13 Mar 2025 Planned number of patients changed from 45 to 36.
- 12 Feb 2025 Status changed from active, no longer recruiting to recruiting.
- 08 Nov 2024 Planned End Date changed from 2 May 2026 to 27 Apr 2026.